Divi's Laboratories Limited vs Indraprastha Medical Corporation Limited

A side-by-side comparison of Divi's Laboratories Limited (DIVISLAB) and Indraprastha Medical Corporation Limited (INDRAMEDCO) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Divi's Laboratories Limited leads DIVISLAB vs INDRAMEDCO on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability22
  • Growth11
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

INDRAMEDCO takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

94.52
P/E ratio
16.10
14.90
P/B ratio
4.46
0.32%
Dividend yield
1.11%
₹96.75
EPS
₹20.03

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

15.32%
Return on equity
24.80%
20.35%
Return on capital
32.43%
32.59%
EBITDA margin
18.00%
24.32%
Net margin
12.39%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
10.49%
12.09%
Profit CAGR (3Y)
28.77%

Size & financial health

DIVISLAB takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.45L Cr
Market cap
₹2,934 Cr
₹10,560 Cr
Revenue
₹1,483 Cr
₹2,568 Cr
Net profit
₹184 Cr
0.00
Debt / equity
0.05
Divi's Laboratories Limited
  • + ["Company has been maintaining a healthy dividend payout of 31.0%", "Company is almost debt free."]
  • − ["Stock is trading at 14.60 times its book value", "The company has delivered a poor sales growth of 8.7% over past five years."]
Indraprastha Medical Corporation Limited
  • + ["Company has delivered good profit growth of 146.9% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 28.8%", "Company is almost debt free.", "Company has delivered good sales growth of 19.3% CAGR over last 5 years"]
  • − []
Divi's Laboratories Limited full analysis Indraprastha Medical Corporation Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.